PUBLIC CONSULTATION ON PHTHALATES IN MEDICAL DEVICES – Guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices
PUBLIC CONSULTATION ON PHTHALATES IN MEDICAL DEVICES
Published in European Commission and Phthalates
More from European CommissionMore posts in European Commission »
- EU – Guidance – Clinical evaluation assessment report template
- EU – Team NB position statement on the requirements for the EU MDR/IVDR Notified Body Partners under the Technical Cooperation Program on Exchange of Medical Device Quality Management System Regulation and ISO 13485 Audit Reports (TCP III)
- UK – MHRA – Medical Device “Certificates of Compliance” / “Attestation of Conformity” have no legal standing under MDR
- EU – Availability and capacity of notified bodies to carry out conformity assessments for COVID-19 related medical devices and in vitro diagnostic medical devices
- EU – New relocated website for medical devices in the EU Commission website
More from PhthalatesMore posts in Phthalates »
- EU – Why are potential dangerous phthalates allowed in medical devices, and who decides if their use is warranted?
- Final guidance – GUIDELINES on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties
- EU – 12th Meeting of the Working Group on Guidelines on benefit – risk assessment of Phthalates in Medical Devices
- EU – Hearing on the SCHEER preliminary Guidelines on the presence of Phthalates in certain medical devices (Brussels, 04 April 2019) – Summary records and presentations now available
Be First to Comment